What ASH abstracts stood out to you most in multiple myeloma? By Lisa X. Lee, MD from UCI Health At ASH this year, it was all about immunotherapy for multiple myeloma. This year’s ASH came on the heels of two major approvals for BCMA directed CAR T, as well as our first approved BCMA bispecific. … Continue reading 2023 ASH Multiple Myeloma [Slides] – Lisa Lee, MD MOASC